Haemonetics Corporation (HAE)Healthcare | Medical Devices | Boston, United States | NYSE
121.72 USD
-0.34
(-0.279%) ⇩
(Oct. 13, 2026, 4 p.m.
EDT)
After hours: 121.72 |
Hot Take ↕ | Oct. 10, 2026, 4:50 a.m. EDT
Haemonetics is displaying aggressive short-term strength, having surged nearly 18% in a single week to approach its fifty-two-week high. Technicals and options flow align, with heavy call positioning at strikes above the current price, signaling that traders are betting on a continuation of this rally. However, the long-term investment case remains mixed. While the forward price-to-earnings ratio is more reasonable than the trailing multiple, the company has suffered two consecutive years of negative annual returns, and the balance sheet carries a high debt-to-equity load. Furthermore, there is no dividend history to provide income. The recent price action appears to be driven by momentum rather than a fundamental turnaround, making it a high-conviction trade for the near term but a speculative hold for the longer horizon. |
| Model | MAE |
|---|---|
| AutoARIMA ✓ | 0.080238 |
| AutoTheta | 0.171545 |
| AutoETS | 0.213397 |
| MSTL | 0.224247 |
Forecast horizon: 45 days | Selected: AutoARIMA
| Forecast Reliability | |
|---|---|
| Score | 37% |
| H-stat | 2.65 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.029 |
| Excess Kurtosis | -0.05 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 140.265 |
| Revenue per Share | 29.081 |
| Market Cap | 5,537,901,056 |
| Trailing P/E | 58.80 |
| Forward P/E | 20.92 |
| Beta | 0.61 |
| Profit Margins | 7.12% |
| Website | https://www.haemonetics.com |
As of Oct. 10, 2026, 4:50 a.m. EDT: Options activity indicates a bullish bias with significant open interest in call strikes ranging from 120 to 140, suggesting speculation on continued upside momentum. Put open interest is concentrated at lower strikes (70 to 110), acting as a floor but with less volume than the call side. Implied volatility remains elevated across expirations, reflecting heightened uncertainty and speculative interest following the recent price surge.
| Attribute | Value |
|---|---|
| 52 Week Change | 1.4529743 |
| Address1 | 125 Summer Street |
| All Time High | 142.11 |
| All Time Low | 5.78125 |
| Ask | 122.25 |
| Ask Size | 100 |
| Audit Risk | 2 |
| Average Analyst Rating | 1.7 - Buy |
| Average Daily Volume10 Day | 848,420 |
| Average Daily Volume3 Month | 731,276 |
| Average Volume | 731,276 |
| Average Volume10Days | 848,420 |
| Beta | 0.608 |
| Bid | 121.53 |
| Bid Size | 100 |
| Board Risk | 1 |
| Book Value | 18.409 |
| City | Boston |
| Compensation As Of Epoch Date | 1,798,675,200 |
| Compensation Risk | 3 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 121.72 |
| Current Ratio | 3.08 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,790,726,400 |
| Day High | 123.77 |
| Day Low | 121.045 |
| Debt To Equity | 140.265 |
| Display Name | Haemonetics |
| Dividend Yield | 0.0 |
| Earnings Call Timestamp End | 1,793,908,800 |
| Earnings Call Timestamp Start | 1,793,908,800 |
| Earnings Growth | 0.029 |
| Earnings Quarterly Growth | -0.03 |
| Earnings Timestamp | 1,793,881,800 |
| Earnings Timestamp End | 1,793,881,800 |
| Earnings Timestamp Start | 1,793,881,800 |
| Ebitda | 358,785,984 |
| Ebitda Margins | 0.26537 |
| Enterprise To Ebitda | 18.082 |
| Enterprise To Revenue | 4.798 |
| Enterprise Value | 6,487,542,272 |
| Eps Current Year | 5.30928 |
| Eps Forward | 5.81808 |
| Eps Trailing Twelve Months | 2.07 |
| Esg Populated | 0 |
| Exchange | NYQ |
| Exchange Data Delayed By | 20 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 102.3452 |
| Fifty Day Average Change | 19.374802 |
| Fifty Day Average Change Percent | 0.18930836 |
| Fifty Two Week Change Percent | 145.29742 |
| Fifty Two Week High | 123.77 |
| Fifty Two Week High Change | -2.0499954 |
| Fifty Two Week High Change Percent | -0.016562942 |
| Fifty Two Week Low | 48.55 |
| Fifty Two Week Low Change | 73.17 |
| Fifty Two Week Low Change Percent | 1.5071061 |
| Fifty Two Week Range | 48.55 - 123.77 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 673,882,200,000 |
| Float Shares | 44,886,936 |
| Forward Eps | 5.81808 |
| Forward P E | 20.920992 |
| Free Cashflow | 312,840,000 |
| Full Exchange Name | NYSE |
| Full Time Employees | 3,009 |
| Fullday Change | -0.33999634 |
| Fullday Change Percent | -0.27854854 |
| Fullday Price | 121.72 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,790,812,800 |
| Gross Margins | 0.59331 |
| Gross Profits | 802,161,984 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.01263 |
| Held Percent Institutions | 1.12463 |
| Implied Shares Outstanding | 45,497,051 |
| Industry | Medical Devices |
| Industry Disp | Medical Devices |
| Industry Key | medical-devices |
| Ir Website | http://phx.corporate-ir.net/phoenix.zhtml?c=72118&p=irol-irhome |
| Is Earnings Date Estimate | 0 |
| Language | en-US |
| Last Fiscal Year End | 1,774,656,000 |
| Last Split Date | 1,354,492,800 |
| Last Split Factor | 2:1 |
| Long Business Summary | Haemonetics Corporation, a medical technology company, provides a suite of hospital technologies solutions. The company operates through Plasma, Blood Center, and Hospital segments. It provides automated plasma collection systems, donor management software, and supporting software solutions, such as NexSys PCS plasmapheresis equipment system and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 tools. The company also offers treatment in electrophysiology, critical care, neurocritical care, trauma, burn surgery, spine surgery, and cancer surgery; SavvyWire, a sensor-guided 3-in-1 guidewire for TAVR procedures; and OptoWire, a pressure guidewire that measures fractional flow reserve and diastolic pressure ratio, as well as fiber optic sensor solutions used in medical devices and other critical industrial applications. In addition, it provides hospital products comprising TEG 6s system, smallest cartridge-based viscoelastic analyzer that provides a comprehensive assessment of a patient's overall hemostasis; and TEG Manager software, which connects various TEG analyzers throughout the hospital, providing clinicians remote access to active and historical test results that inform treatment decisions. Further, the company offers Cell Saver Elite +, an autologous blood recovery system for cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological surgeries;vascular closure products comprise VASCADE 5F, VASCADE 6/7F, VASCADE MVP XL, and VASCADE MVP, a technology platform which offers catheter-based delivery system and leverages the natural clot-inducing properties of collagen; and transfusion management solutions. It sells its products through direct sales force and independent distributors. The company was founded in 1971 and is headquartered in Boston, Massachusetts. |
| Long Name | Haemonetics Corporation |
| Market | us_market |
| Market Cap | 5,537,901,056 |
| Market State | POSTPOST |
| Max Age | 86,400 |
| Message Board Id | finmb_94613 |
| Most Recent Quarter | 1,782,518,400 |
| Net Income To Common | 96,287,000 |
| Next Fiscal Year End | 1,806,192,000 |
| Non Diluted Market Cap | 4,859,994,987 |
| Number Of Analyst Opinions | 10 |
| Open | 122.8 |
| Operating Cashflow | 328,148,992 |
| Operating Margins | 0.17932 |
| Overall Risk | 2 |
| Payout Ratio | 0.0 |
| Peg Ratio | 1.93 |
| Phone | 781 848 7100 |
| Post Market Change | 0.0 |
| Post Market Change Percent | 0.0 |
| Post Market Price | 121.72 |
| Post Market Time | 1,791,934,204 |
| Previous Close | 122.06 |
| Price Eps Current Year | 22.925896 |
| Price Hint | 2 |
| Price To Book | 6.6119833 |
| Price To Sales Trailing12 Months | 4.096041 |
| Profit Margins | 0.07122 |
| Quick Ratio | 1.674 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | buy |
| Recommendation Mean | 1.72727 |
| Region | US |
| Regular Market Change | -0.339996 |
| Regular Market Change Percent | -0.278549 |
| Regular Market Day High | 123.77 |
| Regular Market Day Low | 121.045 |
| Regular Market Day Range | 121.045 - 123.77 |
| Regular Market Open | 122.8 |
| Regular Market Previous Close | 122.06 |
| Regular Market Price | 121.72 |
| Regular Market Time | 1,791,921,602 |
| Regular Market Volume | 829,189 |
| Return On Assets | 0.06598 |
| Return On Equity | 0.111999996 |
| Revenue Growth | 0.056 |
| Revenue Per Share | 29.081 |
| Sand P52 Week Change | 0.17502642 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 4 |
| Shares Outstanding | 45,497,051 |
| Shares Percent Shares Out | 0.0668 |
| Shares Short | 3,037,763 |
| Shares Short Previous Month Date | 1,788,134,400 |
| Shares Short Prior Month | 2,863,501 |
| Short Name | Haemonetics Corporation |
| Short Percent Of Float | 0.078099996 |
| Short Ratio | 5.23 |
| Source Interval | 15 |
| State | MA |
| Symbol | HAE |
| Target High Price | 140.0 |
| Target Low Price | 86.0 |
| Target Mean Price | 122.2 |
| Target Median Price | 124.0 |
| Total Cash | 224,516,992 |
| Total Cash Per Share | 4.935 |
| Total Debt | 1,174,157,952 |
| Total Revenue | 1,352,013,056 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | 2.07 |
| Trailing P E | 58.801933 |
| Trailing Peg Ratio | 1.6923 |
| Triggerable | 1 |
| Two Hundred Day Average | 75.963 |
| Two Hundred Day Average Change | 45.757004 |
| Two Hundred Day Average Change Percent | 0.6023591 |
| Type Disp | Equity |
| Volume | 829,189 |
| Website | https://www.haemonetics.com |
| Zip | 2,110 |